<DOC>
	<DOCNO>NCT02439411</DOCNO>
	<brief_summary>The purpose study analyze whether Dabrafenib +/- Trametinib effective overall survival , response rate toxicity program .</brief_summary>
	<brief_title>Retrospective Analysis Dabrafenib +/- Trametinib Compassionate Use Experience Spain</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Patients receive least one dose dabrafenib combination trametinib part compassionate use treatment metastatic melanoma , deadline start treatment April 30 , 2014 . Patients history available .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>